Head to head
BPC-157 against KLOW blend
A single peptide against a four peptide vial. In a typical KLOW blend GHK-Cu is 62.5 percent of the powder, so anyone dosing by units is mostly dosing a copper peptide, with roughly 7.9 mg of elemental copper in the vial. No study has tested the combination in any species.
Column A
BPC-157Body Protection Compound 157
A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting.
Column B
KLOW blendKLOW (GHK-Cu + KPV + BPC-157 + TB-500)
A four-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of KPV, BPC-157 and TB-500, sold for repair and inflammation. No study has tested the combination in any species. GHK-Cu is 62.5% of the powder, so the vial carries roughly 7.9 mg of elemental copper and anyone dosing KLOW by units is mostly dosing a copper peptide.
Side by side, on the facts we can check
| Attribute | BPC-157 | KLOW blend |
|---|---|---|
| Category | Healing & Recovery | Healing & Recovery |
| FDA status | Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action | Not approved, and the combination has never been evaluated by any regulator. FDA staff evaluated BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data along with mislabelled products in the market. |
| Half-life | Under 30 minutes in plasma in a two-person pilot; the animal literature describes effects lasting hours to days. | Not defined for the blend, and the components differ. No pharmacokinetic study of the mixture exists. |
| Molecular weight | 1,419.5 Da | A mixture. GHK-Cu is about 403 Da as the copper complex, KPV 342.4 Da, BPC-157 1,419.5 Da, and the Ac-LKKTETQ fragment sold as TB-500 about 889 Da. |
| Mechanism | In animal work BPC-157 promotes angiogenesis, interacts with the nitric oxide system, and raises growth hormone receptor expression and growth factor signaling in tendon fibroblasts. No receptor or molecular target has been identified, which FDA's 2026 evaluation gave as one reason it could not judge biological plausibility. Human mechanistic work is limited to the observation that the peptide was not detectable in plasma after rectal dosing, and to a two-person pilot consistent with a plasma half-life under 30 minutes, against effects that animal studies describe as lasting hours to days. | Assumed to be the sum of the parts, and assumed is the operative word. GHK-Cu carries copper into tissue and has been shown in culture and in rat wound chambers to drive collagen and glycosaminoglycan production. KPV is the C-terminal tripeptide of alpha-MSH and blocks NF-kB and MAP kinase signalling in intestinal epithelial and immune cells. BPC-157 and TB-500 act through the tissue-repair pathways described on their own pages. No paper describes what these four do in the same syringe, whether the effects add, overlap or interfere, or whether an acidic copper complex is compatible in solution with three other peptides over the weeks a vial stays in a fridge. |
| Human studies cited | 5 | 2 |
| Legal status, US | Not approved; research use only | Not approved; sold 'for research use only' |
Frequently asked questions
What is the difference between BPC-157 and KLOW blend?
BPC-157: A pentadecapeptide with a large animal literature on tendon, ligament, muscle and gut healing, and a small human record: two rectal-enema studies run in Croatia, three uncontrolled clinic reports, and a randomized Phase 2 injury trial now recruiting. KLOW blend: A four-peptide vendor blend, typically 50 mg GHK-Cu with 10 mg each of KPV, BPC-157 and TB-500, sold for repair and inflammation. No study has tested the combination in any species. GHK-Cu is 62.5% of the powder, so the vial carries roughly 7.9 mg of elemental copper and anyone dosing KLOW by units is mostly dosing a copper peptide.
Which has stronger research evidence, BPC-157 or KLOW blend?
This database does not grade compounds. It counts what was run in people: 5 of the 12 studies cited on the BPC-157 profile were human work, against 2 of 10 for KLOW blend. Those counts are of our own citation lists and understate any larger literature, and neither is a recommendation.
Are BPC-157 and KLOW blend FDA-approved?
BPC-157: Not FDA-approved. Removed from Category 2 (April 2026); PCAC voted 8 to 6, one abstention, to recommend for compounding (July 2026) against the FDA reviewers' recommendation; awaiting FDA action. KLOW blend: Not approved, and the combination has never been evaluated by any regulator. FDA staff evaluated BPC-157 for the July 2026 Pharmacy Compounding Advisory Committee and found no adequate human data along with mislabelled products in the market..
Related posts
Blog articles that cover BPC-157 or KLOW blend, newest first.
- Healing & Recovery / Sep 8, 2026 / 9 minPeptides for Joint Pain: BPC-157, TB-500, Lorecivivint, Pentosan and Collagen Peptides, Evidence Tiered
- Healing & Recovery / Sep 8, 2026 / 8 minPeptides for Gut Health: BPC-157, KPV and Larazotide Ranked by Human Evidence
- Safety / Sep 8, 2026 / 9 minPeptide Side Effects by Class: What Is Documented, What Is Anecdotal
- Safety / Sep 8, 2026 / 8 minHow to Read a Peptide Certificate of Analysis: HPLC Purity, Mass Spec Identity, Endotoxin, and Janoshik Verification
Reviewed Sep 2026. This page sets two published records side by side. It is educational, it is not medical advice, and it contains no dosing protocols or recommendations for personal use.